180 related articles for article (PubMed ID: 10866684)
1. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
[TBL] [Abstract][Full Text] [Related]
2. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
3. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
Gregory MA; Hann SR
Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
5. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
[TBL] [Abstract][Full Text] [Related]
6. Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis.
Cowling VH; Turner SA; Cole MD
Oncogene; 2014 Jul; 33(27):3519-27. PubMed ID: 24013231
[TBL] [Abstract][Full Text] [Related]
7. Emerging molecular networks in Burkitt's lymphoma.
Mangani D; Roberti A; Rizzolio F; Giordano A
J Cell Biochem; 2013 Jan; 114(1):35-8. PubMed ID: 22903691
[TBL] [Abstract][Full Text] [Related]
8. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
10. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
13. The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro.
Alexandrova N; Niklinski J; Bliskovsky V; Otterson GA; Blake M; Kaye FJ; Zajac-Kaye M
Mol Cell Biol; 1995 Sep; 15(9):5188-95. PubMed ID: 7651436
[TBL] [Abstract][Full Text] [Related]
14. c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.
Scheller H; Tobollik S; Kutzera A; Eder M; Unterlehberg J; Pfeil I; Jungnickel B
Oncogene; 2010 Feb; 29(6):888-97. PubMed ID: 19881537
[TBL] [Abstract][Full Text] [Related]
15. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein.
Fest T; Guffei A; Williams G; Silva S; Mai S
Oncogene; 2005 Apr; 24(18):2944-53. PubMed ID: 15735723
[TBL] [Abstract][Full Text] [Related]
16. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
[TBL] [Abstract][Full Text] [Related]
17. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
18. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
19. Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
Rabbitts TH; Forster A; Hamlyn P; Baer R
Nature; 1984 Jun 14-20; 309(5969):592-7. PubMed ID: 6547209
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
